Roquefort Therapeutics PLC (LSE:ROQ) said trading in its shares has commenced on the OTCQB Venture Market in the US under the ticker ‘ROQAF’.
The biotech company, whose primary listing is on the main market of the London Stock Exchange, said cross trading on the OTCQB will give it access one of the world's largest investment markets to expand its reach into a broader pool of investors.
"Joining the OTCQB market provides Roquefort Therapeutics access to a significant investment market, and with minimal ongoing costs associated and no additional reporting requirements, is a positive step forward for the company,” said Stephen West, Roquefort Therapeutics’ executive chairman.
READ: Roquefort Therapeutics acquiring biotech set up by Nobel Laureate
“Having cross trading capabilities is important for the development of Roquefort Therapeutics and we believe this listing will provide the company access to US investors, both institutional and retail, significantly increasing our exposure and trading liquidity.
“Our aim is to build a leading biotech company focused on oncology drugs and we are pleased to be offering US investors the opportunity to participate in our growth," West added.
Roquefort Therapeutics has appointed MCAP LLP as its OTCQB Sponsor.